Vericel Corporation filings document regulatory disclosures for a commercial-stage biopharmaceutical company focused on cell therapies and specialty biologics for sports medicine and severe burn care. Recent Form 8-K reports furnish operating and financial results, preliminary estimates, guidance updates and business highlights tied to MACI, Epicel and NexoBrid.
Proxy and annual meeting filings describe board elections, advisory votes on executive compensation, auditor ratification and other shareholder voting matters. The filing record also identifies Vericel as a Michigan corporation and provides formal disclosure around governance, financial reporting events and product-related commercial performance.
Form 144 filing for Vericel Corporation (VCEL) shows a planned sale of 10,000 common shares held by the reporting person through Fidelity Brokerage Services. The filing lists an approximate aggregate market value of $357,700 for the shares to be sold and indicates the shares represent part of an option granted on 02/11/2020 and acquired on 09/02/2025, with cash payment at exercise. The issuer's total shares outstanding are shown as 50,460,205, so the proposed block is a small fraction of the company. The filing also discloses a prior sale of 10,000 common shares by the same person on 06/02/2025 for $400,924. The notice affirms the signer does not possess undisclosed material adverse information.
Kevin F. McLaughlin, a director of Vericel Corporation (VCEL), exercised 7,000 stock options at an exercise price of $2.76 and immediately sold 7,000 common shares at $35.92 on 08/06/2025 pursuant to a Rule 10b5-1 trading plan adopted March 11, 2024.
After these transactions the filing reports beneficial ownership of 15,100 common shares. The filing also states the options originally granted on May 4, 2016 represented the right to purchase 15,000 shares and shows 0 derivative securities beneficially owned following the reported transactions.